A large retrospective cohort study evaluating real-world prescription claims in the United States has revealed that initiating low-sodium oxybate therapy is associated with a marked decrease or complete cessation of alerting agent use among patients diagnosed with central disorders of hypersomnolence. The investigation, designated the Idiopathic Hypersomnia and Narcolepsy Treatment Patterns and Descriptive Epidemiology study, analyzed longitudinal health insurance records spanning more than sixteen years to trace how patients navigate pharmacotherapy following diagnosis. Investigators observed that among individuals who had routinely received alerting agents prior to starting low-sodium oxybate, 42.9 percent of patients with narcolepsy and 53.1 percent of patients with idiopathic hypersomnia successfully reduced their dosage or discontinued alerting agents entirely within 180 days. Concurrently, the study uncovered substantial treatment gaps across clinical practice, demonstrating that 30.9 percent of individuals diagnosed with narcolepsy and 54.1 percent of those diagnosed with idiopathic hypersomnia received no recognized disease-specific pharmacotherapy across the entire observation period, underscoring systemic barriers and persistent unmet therapeutic needs.
Central disorders of hypersomnolence represent debilitating, chronic neurological conditions predominantly characterized by profound excessive daytime sleepiness that severely impacts daily functional capacity and overall health-related quality of life. Narcolepsy is clinically categorized into type 1 and type 2 subtypes, presenting secondary complications such as severe sleep fragmentation, sleep paralysis, hypnagogic or hypnopompic hallucinations, and sudden episodes of muscle weakness triggered by strong emotions known as cataplexy, which is unique to type 1. Conversely, idiopathic hypersomnia manifests as persistent daytime sleepiness frequently accompanied by severe sleep inertia, prolonged nonrestorative nocturnal sleep, and prolonged, unrefreshing daytime naps that fail to alleviate exhaustion. Because curative treatments do not exist for either pathology, long-term therapeutic regimens focus primarily on mitigating debilitating symptoms and restoring functional daytime alertness. Standard treatment pathways historically relied on traditional stimulant medications or wake-promoting alerting agents alongside off-label antidepressants, with low-sodium oxybate emerging as an advanced formulation engineered to match the efficacy of conventional sodium oxybate while providing a 92 percent reduction in sodium intake to lessen cardiovascular burden.
To rigorously examine real-world clinical practices, researchers analyzed administrative claims and linked electronic health record data extracted from the Optum Market Clarity database between July 1, 2007, and September 30, 2023. The dataset encompasses longitudinal records representing more than 70 million insured lives across diverse delivery networks, matching closed medical claims with inpatient and ambulatory encounters through deterministic validation protocols. Patient entry into the study cohort spanned from July 2007 through September 2022, requiring a minimum continuous medical and pharmacy enrollment period of 180 days prior to initial diagnosis, permitting a maximum enrollment gap of 60 days. The narcolepsy cohort required at least two documented diagnostic claims separated by at least one day in patients aged seven years or older, while idiopathic hypersomnia required at least one diagnostic claim in adults aged eighteen years or older, with rigorous exclusion criteria applied to eliminate overlapping diagnoses or documented cataplexy within the idiopathic hypersomnia population.
The qualifying patient populations comprised 43,252 individuals diagnosed with narcolepsy and 24,528 individuals diagnosed with idiopathic hypersomnia, establishing a comprehensive sample reflecting diverse real-world demographics. Within the narcolepsy cohort, the mean participant age was 42.8 years with a standard deviation of 17.2 years, and 62.9 percent of patients were female, 72.0 percent identified as white, and 63.3 percent were enrolled in commercial insurance plans. Diagnostically, 78.2 percent of the narcolepsy cohort held claims specifically indicative of type 2 narcolepsy, with prevalent comorbid conditions including obstructive sleep apnea in 41.9 percent, hypertension in 40.2 percent, and clinical anxiety in 30.1 percent. The idiopathic hypersomnia cohort exhibited a mean age of 45.8 years with a standard deviation of 15.7 years, comprising 61.7 percent female individuals, 73.6 percent white individuals, and 67.5 percent commercially insured participants. Furthermore, 66.9 percent of idiopathic hypersomnia patients were categorized as experiencing long sleep time, accompanied by high baseline burdens of medical comorbidities, including hypertension in 43.4 percent, obstructive sleep apnea in 42.6 percent, and hyperlipidemia in 29.0 percent.
Longitudinal evaluations of the narcolepsy cohort demonstrated extensive complexity across successive therapeutic regimens over a median clinical follow-up duration of 2.5 years. Notably, 30.9 percent of the entire narcolepsy population received no prescription fills meeting the 30-day minimum supply criteria for study drugs throughout their monitored period, experiencing a median untreated follow-up of 1.8 years. Marked demographic disparities emerged within this untreated group: 49.3 percent of Black patients received no therapeutic interventions compared with 28.0 percent of white patients, while older adults aged 65 years and above displayed the highest rate of non-treatment at 48.0 percent. When examining the subset of 10,220 patients who entered the narcolepsy cohort following the formal approval of low-sodium oxybate, 35.3 percent remained completely untreated over a median follow-up of 1.5 years. In an additional sensitivity analysis restricted to 11,363 individuals who underwent confirmatory polysomnography or multiple sleep latency testing, 28.6 percent remained untreated over a median observation of 2.1 years, indicating that non-treatment persists even following formal diagnostic sleep testing.
Patterns observed in the idiopathic hypersomnia cohort similarly revealed pronounced treatment deficits and intricate management pathways over a median observation period of 2.6 years. Across the primary study cohort, 54.1 percent of patients diagnosed with idiopathic hypersomnia received no recognized pharmaceutical treatments of interest, with a median follow-up of 2.4 years documented among untreated individuals. Racial disparities were highly pronounced, as 69.3 percent of Black patients remained untreated compared to 51.5 percent of white patients, while non-treatment reached 76.0 percent among patients aged 65 and older. Individuals diagnosed with idiopathic hypersomnia without long sleep time were more frequently untreated than those exhibiting long sleep durations, displaying untreated proportions of 59.3 percent versus 51.5 percent, respectively. In the post-approval sensitivity cohort of 2,971 patients, 50.3 percent received no therapy, whereas among 2,720 individuals who had documented multiple sleep latency testing, the untreated proportion dropped substantially to 22.4 percent, demonstrating that documented objective physiological evaluation strongly correlates with therapy initiation.
When pharmacotherapy was initiated, alerting agents overwhelmingly served as the primary first-line therapeutic intervention across both neurological cohorts. Among treated narcolepsy patients, alerting agent monotherapy constituted 76.5 percent of initial regimens, representing 52.9 percent of the total cohort, and was initiated after a median duration of 19.0 days following diagnosis compared to 21.0 days for any treatment overall. Other therapies, including antidepressants such as venlafaxine, fluoxetine, atomoxetine, and imipramine, represented the second most common first-line approach at 13.1 percent of treated cases, though 85.8 percent of all treated narcolepsy patients eventually underwent subsequent regimen adjustments. Similarly, for idiopathic hypersomnia, alerting agents formed 67.9 percent of initial treatments, initiated after a median interval of 17.0 days, followed by non-alerting agents at 21.4 percent. Among individuals with idiopathic hypersomnia who underwent prior sleep latency testing, alerting agents represented 82.6 percent of first-line therapies, initiated rapidly after a median of 6.5 days, while overall treatment changes occurred in 86.5 percent of first-line initiators.
Among 1,032 patients with narcolepsy who initiated low-sodium oxybate, 788 individuals possessed documented alerting agent prescription claims in the 180 days preceding initiation, providing a defined window to assess therapeutic adjustments. Following low-sodium oxybate introduction, 26.3 percent of these patients reduced their average daily alerting agent dosage or decreased the total number of distinct alerting agents filled, while an additional 16.6 percent completely discontinued alerting agent therapy. An additional 5.3 percent of patients switched to an alternative alerting agent, whereas 32.6 percent maintained their baseline dosage and medication selection unchanged. Prior sodium oxybate experience influenced these patterns: 38.2 percent of 505 patients transitioning from conventional sodium oxybate reduced or discontinued alerting agents, whereas 51.2 percent of 283 oxybate-naive patients achieved reduction or discontinuation. Patients reducing or discontinuing alerting agents were younger on average, had a higher female representation, and exhibited an increased prevalence of medical comorbidities, including anxiety, depressive disorders, cardiovascular disease, hypertension, and sleep apnea.
Significant alerting agent de-escalation was likewise confirmed in the idiopathic hypersomnia cohort, where 96 of 120 patients initiating low-sodium oxybate had documented alerting agent therapy during baseline assessment. Within the subsequent 180 days, 37.5 percent of these individuals demonstrated an alerting agent dosage reduction, while 15.6 percent completely discontinued alerting agent prescriptions, culminating in a combined 53.1 percent reduction or discontinuation rate. Switching between different alerting agents occurred in 8.3 percent of patients, while 21.9 percent maintained unchanged regimens. Phenotypic disease subtype significantly correlated with de-escalation: among 74 individuals diagnosed with long sleep time, 58.1 percent reduced or discontinued alerting agents, compared with only 36.4 percent among the 22 patients without long sleep time. Much like the narcolepsy cohort, individuals who successfully reduced or stopped alerting agent therapy demonstrated higher baseline comorbid disease rates, exhibiting greater frequencies of mood disorders, depressive disorders, obesity, hyperlipidemia, and obstructive sleep apnea than those maintaining steady alerting agent doses.
The study authors highlighted that reducing alerting agent reliance represents a crucial clinical strategy for managing polypharmacy and mitigating cardiovascular risks, particularly given the elevated rates of hypertension and metabolic comorbidities identified across both conditions. Many health insurance plans mandate prior authorization and step therapy policies requiring sequential trials of generic stimulants before approving access to branded oxybate formulations, suggesting that post-initiation alerting agent reductions may reflect patients finally transitioning to an effective preferred monotherapy. However, researchers noted inherent limitations in retrospective claims analyses, including potential diagnostic miscoding, an estimated 20 percent false-positive rate for claims-based narcolepsy algorithms, the absence of uninsured populations, and the lack of clinical verification regarding true medication compliance. Because the study design was exploratory and descriptive, observed associations cannot prove direct causality, yet the findings provide clear real-world evidence that low-sodium oxybate initiation frequently allows meaningful reductions in stimulant burdens while underscoring systemic barriers that leave substantial patient populations without access to essential treatment.
Subject of Research: Real-world treatment patterns and alerting agent utilization changes following low-sodium oxybate initiation in narcolepsy and idiopathic hypersomnia
Article Title: Narcolepsy and Idiopathic Hypersomnia Real-World Treatment Patterns and Changes in Alerting Agent Use After Low-Sodium Oxybate Initiation: A Retrospective Claims Analysis
Article References: Markt, S. C., Whalen, M., Alexander, J. K., Drachenberg, C., Gavrielov-Yusim, N., Beaty, S., Poole, E. M., Kroner, J., Attinson, D., Desai, S., Black, J., & Thorpy, M. J. (2026). Narcolepsy and Idiopathic Hypersomnia Real-World Treatment Patterns and Changes in Alerting Agent Use After Low-Sodium Oxybate Initiation: A Retrospective Claims Analysis. Neurology and Therapy, 15(6), 3393-3411. https://doi.org/10.1007/s40120-026-01046-3
Image Credits: AI Generated
DOI: 10.1007/s40120-026-01046-3
Keywords: narcolepsy, idiopathic hypersomnia, low-sodium oxybate, alerting agents, excessive daytime sleepiness, cataplexy, wake-promoting agents, sleep medicine, real-world evidence, claims analysis, Optum Market Clarity, polypharmacy, stimulant reduction, step therapy, central disorders of hypersomnolence, sleep inertia
News Source: Ophelia Keating. (November 20, 2026). Low-Sodium Oxybate Initiation Linked to Reduced Alerting Agent Use in Hypersomnia. Scienmag.



